AxoGen, Inc.

NASDAQ:AXGN

Medical - Devices

Healthcare
$56.95 +0.56%

+$0.25 today

Market cap
$3.40B
Beta
1.12
P/E (TTM)
-73.4
EPS (TTM)
-$0.61
52W Low $9.35High $45.83

Volume 2.11M

Average 1.08M

AXGN Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

AxoGen, Inc.NASDAQ: AXGN

Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026

Depreciation & amortization dips below year-ago levels

Q3 FY2026 depreciation & amortization of $1.69M fell 8.0% year over year, behind the +19.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 21.3% from the prior quarter. Over 3 fiscal years it compounded at +19.1% a year.

Context

  • Depreciation & amortization amounted to 3.6% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -8.0% toward the trailing-twelve-month pace of +19.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.69M-21.3% QoQ
Last fiscal yearDec 2025
$8.19M+4.5% YoY
LTMSep 2026
$8.91M+19.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.0%——
1 year+4.5%——
3-year CAGR+19.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
8.19M USD
Year-over-year change
+4.5%
4-year CAGR
+14.7%

Depreciation & Amortization vs competitors

How AXGN compares with its peers on the latest reported figures

  • AXGN's LTM Sep 2026 depreciation & amortization of $8.91M is the 3rd largest of the 7 companies compared; the peer median is $5.77M.
  • Its year-over-year change of +19.5% is the 4th highest of 7, against a peer median of +21.7%.
  • Depreciation & amortization amounts to 3.3% of revenue for AXGN, versus a peer median of 4.2%.
AXGN Competitors Peer median
Depreciation & Amortization for AXGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$30.95M +45.2%+35.9%6.0%
MDXGMiMedx Group, Inc.LTM Mar 2026$16.5M +94.2%+54.4%4.2%
AXGNAxoGen, Inc.LTM Sep 2026$8.91M +19.5%+19.1%3.3%
HUMAHumacyte, Inc.LTM Mar 2026$6.86M +34.4%-13.4%340.1%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$4.68M +9.1%+59.3%3.8%
TELATELA Bio, Inc.LTM Jun 2026$1M -5.9%-5.2%1.3%
BSEMBioStem Technologies, Inc.LTM Jun 2026$384.08K -31.7%+16.1%—
Peer median (excluding AXGN) $5.77M+21.7%+26.0%4.2%

Competitors are the stored peer set for AXGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.99M)(28.95M)(21.72M)(9.96M)(15.7M)
Depreciation & Amortization4.74M4.85M5.55M7.84M8.19M
Deferred Income Tax3.37M0000
Stock-Based Compensation10.92M15.59M14.42M15.91M30.11M
Change in Working Capital(6.28M)(9.56M)(4.39M)(10.04M)(24.62M)
Accounts Receivables(499K)(4.64M)(2.69M)392K(2.46M)
Inventory(7.48M)(3.66M)(6.05M)(10.16M)(9.19M)
Accounts Payables(270K)660K6.51M125K(7.16M)
Other Working Capital1.97M(1.93M)(2.15M)(399K)(5.81M)
Other Non-Cash Items831K2M415K797K2.83M
Operating Cash Flow(13.41M)(16.07M)(5.72M)4.54M812K
Capital Expenditures(28.4M)(21.25M)(14.92M)(4.52M)(3.75M)
Acquisitions (Net)(589K)3.2M000
Purchases of Investments(68.7M)(39.25M)(10.2M)(5.77M)(13.72M)
Sales of Investments72.5M57.3M44.37M014M
Other Investing Activities1.54M(3.2M)(1.05M)(1.42M)(1.85M)
Investing Cash Flow(23.65M)(3.2M)19.25M(10.3M)(5.32M)
Debt Repayment14.99M(12K)(10K)(10K)(32K)
Common Stock Issued5.47M1.81M1.96M2.3M10.53M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow20.45M1.79M1.95M2.29M10.5M
Effect of Forex Changes00000
Net Change in Cash(16.6M)(17.47M)15.49M(3.47M)5.99M
Free Cash Flow(41.81M)(37.32M)(20.63M)11K(2.93M)

AxoGen, Inc.

NASDAQ:AXGN

Intrinsic Alpha fair value

Locked

Current Price

$56.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.